Sen-Jam Pharmaceutical announced the preliminary results from its recently completed Phase 2 clinical trial evaluating the safety and efficacy of SJP-002C, a novel therapeutic for the treatment of Upper Respiratory Infections such as COVID-19.
Key Highlights of the Trial Results:
- Safety: SJP-002C demonstrated an exceptional safety profile, with no adverse events reported during the trial period, highlighting its potential as a safe therapeutic option for COVID-19.
- Efficacy: The therapeutic significantly improved symptom reduction during the critical early stages of treatment, particularly on days 1 and 2.
These findings reinforce SJP-002C's promise as a groundbreaking therapeutic for COVID-19 and Upper Respiratory Infections, demonstrating both safety and early efficacy. While further studies are needed to validate its statistical and clinical significance, the trial results encourage continued development and exploration of the therapeutic's broader potential.
"The strong safety profile and early symptom improvements are promising indicators of SJP-002C's potential to make a meaningful impact in COVID-19 care," said Jackie Iversen RPh MS, Chief Clinical Officer and Co-Founder, Sen-Jam Pharmaceutical. "We are energized by these results and remain committed to refining the efficacy of this therapeutic to serve a broader population."
Sen-Jam is actively reviewing additional clinical data to deepen its understanding of SJP-002C's performance and efficacy. The company is also exploring opportunities for follow-up studies that could expand the scope of the therapeutic's application to broader patient populations and conditions.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!